One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke.

One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke. Curr Neuropharmacol. 2015 Dec 7; Authors: Chen HS, Qi SH, Shen JG Abstract Tissue plasminogen activator (t-PA) is the only FDA approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential resolutions is to use adjunct therapies to reduce the side effects and extend t-PA's therapeutic time window. However, therapies modulating single target seems not satisfying, and a multi-target strategy is warranted to resolve such complex disease. Recent years, large amounts of efforts have been made to explore the active compounds from herbal supplements to treat ischemic stroke. Some of the natural compounds revealed both neuro- and blood-brain-barrier (BBB)-protective effects by concurrently targeting on multiple cellular signaling pathways in cerebral ischemia-reperfusion injury. Thus, those compounds are potential one-drug-multi-target agents to be combined with t-PA in treatment of ischemic stroke. In this review article, we summarize current progress in understanding the molecular targets involving in t-PA-mediated HT and neurotoxicity in ischemic brain injury. Based on those targets, we select 23 promising compounds from currently available literatur...
Source: Current Neuropharmacology - Category: Drugs & Pharmacology Authors: Tags: Curr Neuropharmacol Source Type: research